Monte Rosa Therapeutics, Inc.
https://www.monterosatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Monte Rosa Therapeutics, Inc.
BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.
Roche Bonds With Monte Rosa To Degrade Molecular Glues
Deal Snapshot: Monte Rosa Therapeutics received $50m up front and may earn more than $2bn in milestone fees from Roche for molecular glue degraders to treat cancer and neurological diseases.
Blueprint Still Confident In CDK2 Inhibitor Despite Partial Hold On Phase I/II Trial
The FDA placed a partial hold on the VELA study of BLU-222 due to some patients experiencing visual toxicity, but the company anticipates reporting data and said it is near identifying Phase II dose.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice